Welcome to our dedicated page for Shoulder Innovations news (Ticker: SI), a resource for investors and traders seeking the latest updates and insights on Shoulder Innovations stock.
Shoulder Innovations develops and commercializes medical technology for the shoulder surgical care market, with implant systems for total and reverse shoulder arthroplasty and related tools for preoperative planning and procedural efficiency. Its ecosystem includes InSet shoulder arthroplasty systems, the ProVoyance planning platform, instrument systems, specialized support and surgeon collaboration.
Company news commonly covers product launches and FDA 510(k) clearances, including additions to the I-Series portfolio, quarterly and annual financial results, enabling-technology partnerships, board and committee changes, and management presentations at medical technology and musculoskeletal conferences.
Shoulder Innovations (NYSE:SI), a commercial-stage medical technology company focused on shoulder surgical care, announced that its management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, FL on Tuesday, June 9, 2026.
Shoulder Innovations (NYSE: SI) reported strong first quarter 2026 growth with net revenue of $16.7 million, up 65% year-over-year. Gross margin improved to 77.7%, while 2,184 implant systems sold rose 51% and average selling price increased 9% to $7,650.
The company raised its 2026 net revenue outlook to $65–$68 million, implying about 37%–44% growth over 2025. Operating expenses increased, resulting in a $9.0 million operating loss and $8.4 million net loss, with cash and securities totaling $108.5 million.
Shoulder Innovations (NYSE: SI) announced the full commercial launch of the InSet™ I-135RFX humeral stem on April 27, 2026. The launch follows a limited market release and additional FDA 510(k) clearance expanding fracture indications, enabling use in primary, revision, and fracture total shoulder arthroplasty.
The I-135RFX is the third InSet humeral stem in three years and uses the company’s InSet lateral-lateral implant philosophy, which independent peer-reviewed research has associated with fewer complications and improved post-operative range of motion.
Shoulder Innovations (NYSE: SI) will release first-quarter 2026 financial results after market close on Wednesday, May 13, 2026. Management will hold a conference call at 4:30 p.m. ET / 1:30 p.m. PT the same day to discuss results.
Dial-in numbers and webcast access are provided for live and archived listening via the company's Investor Relations website.
Shoulder Innovations (NYSE: SI) reported strong 2025 results with Q4 net revenue $14.4M (+65% YoY) and full-year net revenue $47.3M (+50% YoY). Gross margin was ~76.5% for the year. Company sold 1,976 implant systems in Q4 and ended 2025 with 134 core and contender surgeons.
SG&A and R&D rose materially, driving a full-year net loss of $40.4M. Cash and marketable securities totaled $124.3M. 2026 revenue guidance: $62M–$65M (≈31%–37% growth).
Shoulder Innovations (NYSE: SI) appointed medtech executive Drew Hykes to its Board of Directors and Compensation Committee, effective February 26, 2026, while Geoff Pardo resigned as an independent director. Hykes brings 25+ years of device experience, including leadership roles at Okami Medical, Inari Medical, and Medtronic.
Management changes signal governance refresh as Shoulder Innovations scales commercial adoption of its shoulder arthroplasty portfolio.
Shoulder Innovations (NYSE: SI) said management will present at the Canaccord Genuity 2026 Musculoskeletal Conference on Tuesday, March 3, 2026 at 2:00 p.m. CT / 12:00 p.m. PT.
According to the company, a live webcast and archived replay will be available via the Investor Relations section of its website.
Shoulder Innovations (NYSE: SI) will release fourth quarter and full year 2025 financial results after market close on March 10, 2026. Management will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on March 10, 2026 to discuss results.
Dial-in numbers are (877) 407-8216 (U.S.) or (412) 902-1015 (international) with access code 13758375. A live and archived webcast will be available in the Investor Relations section at https://ir.shoulderinnovations.com/.
Shoulder Innovations (NYSE: SI) said management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT on February 10–11, 2026. The presentation offers an investor update and engagement with industry attendees and analysts.
Shoulder Innovations (NYSE: SI) announced on December 3, 2025 a strategic partnership with Interventional Systems (INS) to develop a shoulder-specific micro-robotic platform that will integrate with Shoulder Innovations' ProVoyance system.
The portable robot is designed for transport directly into the operating room and aims to improve surgical precision, workflow efficiency, and enable new clinical approaches in total and reverse shoulder arthroplasty, with a stated focus on ambulatory surgery centers (ASCs). The companies said the solution targets high implementation costs, mobility limits, perioperative inefficiencies, and steep learning curves associated with existing robotic systems.